Johanna ÁlvarezGabriela Rozo-PazDaniela Castellanos-LeguizamónJavier Baena-Del ValleAlonso Vera-TorresViviana Barrera-PenagosDaniel González‐MorenoDiana Marcela Grajales-UrregoRocío López2026-03-222026-03-22202510.22541/au.174664998.87015473/v1https://doi.org/10.22541/au.174664998.87015473/v1https://andeanlibrary.org/handle/123456789/84442Background. Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate despite treatment. This study compares the expression of C-Myc and p53 with clinicopathological, molecular, and prognostic factors in PDAC patients at the Fundación Santa Fe University Hospital in Bogotá. Methodology. This descriptive-analytical study included 95 PDAC patients, 55 of whom underwent surgical resection and 40 were only biopsied. Clinicopathological data was obtained from histological analyses and medical records. Expression of C-Myc and p53 was determined by immunohistochemistry. Statistical analysis was done using R-studio version 2023.12.1. Results. The study group consisted of 52 women (54.7%) and 43 men (45.3%), aged 41-89 years (M = 66.8). No significant associations were found between molecular marker expression and clinicopathological variables. However, patients with PDAC in the pancreas body or liver metastases had a higher likelihood of surviving less than 3 years. Among surgical patients (N = 54), 38 expressed C-Myc and 39 expressed p53. Aberrant p53 expression was linked to decreased disease-free survival in patients with a <3-year survival post diagnosis (t[23] = -2.42; p < .05). Similarly, higher C-Myc expression was seen in patients with postsurgical recurrence with a <3-year survival post diagnosis (t[21] = -2.28; p < .05). Conclusion. Targeted therapies for these genes may improve PDAC prognosis. Further research should investigate other biomarkers and their expression in neoplastic and preserved pancreatic tissue.enPancreatic ductal adenocarcinomaInternal medicineOncologyMedicineAssociation (psychology)Expression (computer science)Cancer researchpreprint